INCB161734 + gemcitabine + nab-paclitaxel

This is an investigational **combination regimen** composed of the selective KRAS G12D inhibitor **INCB161734** (a novel, potent, and orally bioavailable small molecule), plus classic cytotoxic chemotherapy agents **gemcitabine** (a nucleoside analog) and **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel). INCB161734 is designed to selectively target tumors with the KRAS G12D mutation by binding to both GDP-bound and GTP-bound forms, inhibiting downstream ERK and PI3K signaling, arresting the cell cycle, and promoting apoptotic cell death. Gemcitabine induces cytotoxicity by incorporation into DNA, leading to apoptosis, while nab-paclitaxel stabilizes microtubules to prevent cell division. The combination is under investigation for synergistic antitumor effects, primarily in advanced pancreatic ductal adenocarcinoma and other solid tumors with KRAS G12D mutations[1][2].